Skip to main content
main-content

Cardiovascular disease and diabetes medication

medwireNews top story

Heart failure poses greatest CV mortality risk after type 2 diabetes diagnosis

Chalkboard image of patient with heart failure

Real-world study findings suggest that heart failure is associated with the greatest increase in mortality risk when compared with other cardiovascular and renal complications among people with newly diagnosed type 2 diabetes.

ADA 2020

DPPOS: No change to cancer risk with long-term metformin use

Tablet device showing the chemical structure of Metformin

Among the latest findings from the DPP Outcomes Study is that long-term use of metformin does not affect the risk for cancer.

medwireNews top story

Cardioprotective benefits of dapagliflozin extend beyond people with diabetes

Heart failure

Treatment with dapagliflozin is associated with a significant reduction in the risk for heart failure worsening or cardiovascular death in people with heart failure and reduced ejection fraction regardless of whether or not they have diabetes, shows an exploratory analysis of DAPA-HF trial data.

medwireNews top story

Meta-analysis demonstrates cardioprotective effect of GLP-1 receptor agonists

Heart and stethoscope

Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

Expert opinion editorial

Cardiorenal syndromes and SGLT2 inhibitor usage

Cardiorenal syndromes and SGLT2 inhibitor usage

Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity [read more].

Get more on: SGLT2 inhibitors | Nephropathy | Cardiovascular disease 

medwireNews top story

Support for metformin cardioprotective effect

Heartbeat

Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.

medwireNews top story

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Kidneys

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

The REWIND trial

Cardiovascular disease (illustration)
Expert opinion editorial

The CAROLINA trial: Make or break for sulfonylureas?

Sulfonylurea pill

Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas. 

Get more on: Sulfonylureas | DPP-4 inhibitors | Other diabetes medications

medwireNews top story

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Heartbeat

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

medwireNews

06-30-2020 | Medications | News

Network meta-analysis highlights research gaps for diabetes medications

A wide-ranging network meta-analysis published in the Annals of Internal Medicine reveals critical knowledge gaps in the use of glucose-lowering medications in people with type 2 diabetes.

06-29-2020 | SGLT2 inhibitors | News

CVD-REAL 2 data support cardiovascular benefits of SGLT2 inhibitors

The latest CVD-REAL 2 data confirm clinical trial findings by showing that SGLT2 inhibitors significantly lower cardiovascular disease risk in people with type 2 diabetes, this time in comparison with DPP-4 inhibitors.

06-24-2020 | Heart failure | Highlight | News

Heart failure poses greatest CV mortality risk after type 2 diabetes diagnosis

Real-world study findings suggest that heart failure is associated with the greatest increase in mortality risk when compared with other cardiovascular and renal complications among people with newly diagnosed type 2 diabetes.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

10-26-2018 | PCSK9 inhibitors | Review | Article

Inhibiting PCSK9: Biology beyond LDL control

Stoekenbroek RM et al. Nat Rev Endocrinol 2018. doi: 10.1038/s41574-018-0110-5

10-15-2018 | Statins | Review | Article

Beyond statins: Who and when to prescribe?

Ganda O. Curr Diab Rep 2018; 18: 126. doi: 10.1007/s11892-018-1087-0

10-08-2018 | Dapagliflozin | Article

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

Soga F et al. Cardiovasc Diabetol 2018; 17: 132. doi: 10.1186/s12933-018-0775-z

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits